Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|July 1, 1998

Supplements and Featured Publications

  • New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
  • Volume 4
  • Issue 7 Suppl

How Far Have We Come in Treating Congestive Heart Failure?

Download PDF: How Far Have We Come in Treating Congestive Heart Failure?

Articles in this issue

almost 28 years ago

Participating Faculty

almost 28 years ago

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

almost 28 years ago

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

almost 28 years ago

Gene Polymorphism Influences Response to Angiotensin Blockade

almost 28 years ago

New Drug Class Offers Benefits in Heart Failure

almost 28 years ago

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

almost 28 years ago

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

almost 28 years ago

European Society of Cardiology: Angiotensin II Antagonists: Why is There So Much Excitement?

almost 28 years ago

What are the Pharmacological Differences Between Angiotensin II Antagonists

almost 28 years ago

Clinical Implications of Differences Between Angiotensin II Antagonists

Related Content